This seminar will discuss the development of one recent Merck compound (MK-8666), a GPR40 receptor – a next generation diabetes type II therapy.  The talk will discuss synthetic challenges for the manufacture route development, the innovated approach to address those challenges.

Manufacturing process development for GPR40 MK-8666: Small molecules, big challenges

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.